Other Events ·
On July 29, 2026, the European Commission granted marketing authorization for the Pfizer-BioNTech 2026-2027 COVID-19…
BNTXBioNTech SE
On July 29, 2026, the European Commission granted marketing authorization for the Pfizer-BioNTech 2026-2027 COVID-19 vaccine formula targeting the XFG variant of the JN.1 lineage. The approval covers individuals aged 6 months and older across all 27 EU Member States, Iceland, Liechtenstein, and Norway. This follows a positive recommendation from the EMA’s Committee for Medicinal Products for Human Use on July 23, 2026. BioNTech has initiated manufacturing of the monovalent vaccine to ensure supply readiness for the upcoming respiratory disease season. BioNTech SE is a global biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases.